Abstract

IntroductionDevelopment of a sarcomatous component in a germ cell tumor is an uncommon phenomenon. Most cases reported have a grim prognosis. Growing teratoma syndrome is also an uncommon phenomenon and occurs in approximately 2% to 7% of non seminomatous germ cell tumors and should be treated surgically.Case presentationWe report the case of a 12-year-old Asian girl with an ovarian mixed germ cell tumor containing a rhabdomyosarcomatous component. She was treated with a germ cell tumor chemotherapy regimen and rhabdomyosarcoma-specific chemotherapy. Towards the end of her treatment, she developed a retroperitoneal mass that was increasing in size. It was completely resected, revealing a mature teratoma, consistent with growing teratoma syndrome. She is still in complete remission approximately three years after presentation.ConclusionThe presence of rhabdomyosarcoma in a germ cell tumor should be treated by a combined chemotherapy regimen (for germ cell tumor and rhabdomyosarcoma). In addition, development of a mass during or after therapy with normal serum markers should raise the possibility of growing teratoma syndrome that should be treated surgically.

Highlights

  • Development of a sarcomatous component in a germ cell tumor is an uncommon phenomenon

  • The presence of rhabdomyosarcoma in a germ cell tumor should be treated by a combined chemotherapy regimen

  • We describe an ovarian mixed germ cell tumor (GCT) with rhabdomyosarcomatous components and elevated serum alpha fetoprotein (AFP) and beta human chorionic gonadotropin (B-HCG) in an adolescent girl

Read more

Summary

Conclusion

The presence of rhabdomyosarcoma in a germ cell tumor should be treated by a combined chemotherapy regimen (for germ cell tumor and rhabdomyosarcoma). Development of a mass during or after therapy with normal serum markers should raise the possibility of growing teratoma syndrome that should be treated surgically

Introduction
Discussion
Findings
Conclusions
13. Mikuz G
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call